Last reviewed · How we verify
Mometasone furoate 440
Mometasone furoate is a corticosteroid that reduces inflammation by binding to glucocorticoid receptors and suppressing inflammatory mediator production.
Mometasone furoate is a corticosteroid that reduces inflammation by binding to glucocorticoid receptors and suppressing inflammatory mediator production. Used for Asthma maintenance therapy, Allergic rhinitis.
At a glance
| Generic name | Mometasone furoate 440 |
|---|---|
| Sponsor | California Allergy and Asthma Medical Group, Inc. |
| Drug class | Inhaled corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Allergy / Immunology |
| Phase | FDA-approved |
Mechanism of action
Mometasone furoate is a potent inhaled corticosteroid that works by activating intracellular glucocorticoid receptors, leading to decreased production of inflammatory cytokines, chemokines, and adhesion molecules. This reduces airway inflammation, mucus production, and bronchial hyperresponsiveness in asthma and allergic rhinitis. The 440 designation typically refers to the dose strength in micrograms.
Approved indications
- Asthma maintenance therapy
- Allergic rhinitis
Common side effects
- Tremor
- Headache
- Pharyngitis
- Oral candidiasis
- Dysphonia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mometasone furoate 440 CI brief — competitive landscape report
- Mometasone furoate 440 updates RSS · CI watch RSS
- California Allergy and Asthma Medical Group, Inc. portfolio CI